Separate terms with OR to return results that match either term.
 
Clear All
9,752 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
55513-0148-10 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0267-01 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0267-10 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0283-01 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0283-10 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0478-01 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
55513-0478-10 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
59676-0600-12 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 14, 2018 In Use
59676-0600-56 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral April 1, 2019 In Use
61703-0360-18 61703-0360 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 No Longer Used
69656-0103-30 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2018 In Use
69656-0103-61 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2020 In Use
70954-0058-10 70954-0058 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
70954-0058-20 70954-0058 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
70954-0058-30 70954-0058 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
70954-0058-40 70954-0058 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
70954-0059-10 70954-0059 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
70954-0059-20 70954-0059 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
70954-0059-30 70954-0059 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
70954-0059-40 70954-0059 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 15, 2019 In Use
23155-0687-41 23155-0687 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 18, 2019 In Use
23155-0688-41 23155-0688 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 18, 2019 In Use
23155-0689-41 23155-0689 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 18, 2019 In Use
67184-0503-01 67184-0503 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 11, 2018 In Use
72579-0011-02 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 In Use
00074-0576-11 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral April 11, 2016 In Use
00074-0576-22 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral April 11, 2016 In Use
00074-0576-30 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral June 15, 2022 In Use
00074-0576-34 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Nov. 21, 2018 In Use
00781-3498-94 00781-3498 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 19, 2022 In Use
00781-3498-95 00781-3498 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 19, 2022 In Use
00143-9385-01 00143-9385 Decitabine Decitabine 50.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous April 15, 2022 In Use
00378-1201-78 00378-1201 Sorafenib Sorafenib Tosylate 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral June 1, 2022 In Use
00409-1045-01 00409-1045 PEMETREXED PEMETREXED 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 27, 2022 In Use
00409-1060-01 00409-1060 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
00409-1061-01 00409-1061 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
00409-1703-01 00409-1703 BORTEZOMIB BORTEZOMIB 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
00409-2188-01 00409-2188 PEMETREXED PEMETREXED 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 27, 2022 In Use
00409-3532-01 00409-3532 PEMETREXED PEMETREXED 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 27, 2022 In Use
00469-1425-21 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 30, 2022 In Use
00469-1425-90 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Nov. 29, 2018 In Use
00469-1725-56 00469-1725 Enzalutamide Xtandi 40.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug. 4, 2020 In Use
00480-4514-01 00480-4514 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 31, 2022 In Use
00480-4515-01 00480-4515 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 31, 2022 In Use
00480-4516-01 00480-4516 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 1, 2022 In Use
00781-3518-76 00781-3518 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 8, 2022 In Use
00781-3519-90 00781-3519 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 8, 2022 In Use
00904-7236-61 00904-7236 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral June 1, 2022 In Use
10019-0991-01 10019-0991 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use

Found 9,752 results in 14 milliseconds — Export these results